AEterna Zentaris Inc AEZS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AEZS is a good fit for your portfolio.
News
-
Aeterna Zentaris Announces Effective Date of Share Consolidation
-
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
-
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
Trading Information
- Previous Close Price
- CAD 11.04
- Day Range
- CAD 10.79–10.94
- 52-Week Range
- CAD 7.64–16.92
- Bid/Ask
- CAD 2.00 / CAD 0.00
- Market Cap
- CAD 13.10 Mil
- Volume/Avg
- 271 / 607
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.zentaris.com
Valuation
|
Metric
|
AEZS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.75 |
Price/Sales | 2.16 |
Price/Cash Flow | — |
Price/Earnings
AEZS
Financial Strength
|
Metric
|
AEZS
|
|---|---|
Quick Ratio | 7.57 |
Current Ratio | 8.01 |
Interest Coverage | — |
Quick Ratio
AEZS
Profitability
|
Metric
|
AEZS
|
|---|---|
Return on Assets (Normalized) | −35.86% |
Return on Equity (Normalized) | −337.80% |
Return on Invested Capital (Normalized) | −63.03% |
Return on Assets
AEZS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tlmlhvfrbs | Xqp | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vzjcxymd | Hkwwplb | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kyxspwpjy | Ngqxbn | $103.7 Bil | |
MRNA
| Moderna Inc | Khtcscy | Dltk | $47.9 Bil | |
ARGX
| argenx SE ADR | Pfdvybfg | Nsw | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Gsrjxwl | Lfd | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qypqytkj | Qtgysb | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lcngjmx | Gfhdxvp | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nmzjnwzt | Lnbmvt | $12.8 Bil | |
INCY
| Incyte Corp | Msfvfnjz | Rkntm | $12.1 Bil |